US3865935A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tableting of erythromycin base
Assignee: Abbott Laboratories
•
Filing: 1972-08-10
•
Granted: 1975-02-11
•
Expires: 1992-08-10
Abstract
Abstract The present invention is directed to a new tableting formulation for compounding of erythromycin base. It is particularly directed to a new oral dosage form of erythromycin base which is stable upon storage but released promptly in the acidic environment of the stomach.
Inventors
- 👤 Anton Helmuth Amann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:29
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K9/00; A61K9/20; A61K9/2004
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
68 words
THE PROCESS OF MAKING A SOLID NON-ENTERIC ERYTHROMYCIN DOSAGE FORM FOR ORAL ADMINISTRATIONS CONSISTING ESSENTIALLY OF THOROUGHLY MIXING A ) ERYTHROMYCIN GRANULES CONTAINING ERYTHROMYCIN BASE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS READILY SOLUBLE OR DISPERSIBLE IN WATER OR ACIDIC ENVIRONMENTS, B) ANHYDROUS SODIUM CITRATE OR SODIUM CITRATE DIHYDRATE, C) AT LEAST ONE LUBRICATING AGENT AND D) AT LEAST ONE DISINTEGRATING AGENT AND TABLETING SAID MIXTURE INTO A UNIT DOSAGE FORM.
Claim 2
Dependent Claim
68 words
THE PROCESS OF MAKING A SOLID NON-ENTERIC ERYTHROMYCIN DOSAGE FORM FOR ORAL ADMINISTRATIONS CONSISTING ESSENTIALLY OF THOROUGHLY MIXING A ) ERYTHROMYCIN GRANULES CONTAINING ERYTHROMYCIN BASE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS READILY SOLUBLE OR DISPERSIBLE IN WATER OR ACIDIC ENVIRONMENTS, B) ANHYDROUS SODIUM CITRATE OR SODIUM CITRATE DIHYDRATE, C) AT LEAST ONE LUBRICATING AGENT AND D) AT LEAST ONE DISINTEGRATING AGENT AND TABLETING SAID MIXTURE INTO A UNIT DOSAGE FORM.
Claim 3
Dependent Claim
27 words
The process of claim 1 wherein said erythromycin granules and said sodium citrate are used in a ratio between 1:0.4 and 1:2 based on anhydrous sodium citrate.
Claim 4
Dependent Claim
13 words
The process of claim 2 wherein said ratio is between 1:0.8 and 1:1.6.
Claim 5
Dependent Claim
23 words
The process of claim 1 wherein said unit dosage form also contains at least one flavoring agent and at least one coloring agent.
Claim 6
Dependent Claim
22 words
The process of claim 4 wherein said tablet contains erythromycin base and sodium citrate in a ratio of between 1:0.8 and 1:1.6.
Claim 7
Dependent Claim
17 words
The process of claim 4 wherein said sodium citrate is used in the form of crystalline powder.
Claim 8
Dependent Claim
12 words
The process of claim 1 wherein said mixture also contains a binder.
Claim 9
Dependent Claim
18 words
The process of claim 1 wherein said tablet is subsequently coated with a non-enteric, pharmaceutically acceptable coating solution.
References Cited (Backward Citations)
US2857312A
Cited
US2798024A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1978-02-10 | 1978-08-12 | 1979-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1982-02-10 | 1982-08-12 | 1983-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1986-02-10 | 1986-08-12 | 1987-02-11 | $7700.00 | Window Closed / Lapsed |